C-SUITe On Deck
Resources
See All
RELATED news
See All
December 12, 2024
In response to the increasing shortage of oncology nurses, The US Oncology Network introduced the Oncology Core Education and Networking (OCEAN) program to improve retention rates and develop foundational oncology knowledge. The OCEAN program focuses on supporting new oncology nurses with essential virtual education sessions, helping them build the confidence and skills needed to provide advanced cancer care. Early results show a 70% knowledge improvement among participants and an impressive 82% retention rate, exceeding the national average.
December 10, 2024
Veeva Systems has launched its latest Vault CRM Suite, including the new Vault CRM Campaign Manager, to streamline commercial operations for the life sciences industry. The platform integrates sales, marketing, and service functions under one unified system, offering unmatched scalability and advanced automation capabilities.
Vault CRM Campaign Manager enables personalized, multichannel marketing campaigns, boosting customer engagement and facilitating precise decision-making. According to Arno Sosna, General Manager of Veeva CRM, this innovation empowers organizations with actionable data insights to enhance collaboration across teams.
Already adopted by over 30 companies, Vault CRM is set to transition major enterprises, including leading biopharma firms, by the end of 2025. This development solidifies Veeva's commitment to delivering modern tools for next-generation commercial strategies.
December 22, 2022
Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762. Phio is a clinical stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intratumorally in preclinical models PH-762 primes an anti-tumor immune response, and inhibits tumor growth. Phio is currently conducting a Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma at the Gustave Roussy Institute, one of the largest cancer centers in Europe. Phio expects to commence a US Phase 1b clinical trial early in the 2nd half of 2023. The initial US trial is expected to focus on the treatment of cutaneous squamous cell carcinoma and other selected cutaneous malignancies, following successful regulatory review of the IND. "Therapeutic interventions for cSCC are limited, and there is increasing unmet medical need. As cSCC tumors comprise approximately 51% of the total incidence of solid tumors in the US, excluding basal cell cancers, we recognize the growing need for alternative therapies for cSCC," said Robert Bitterman, Phio's Principal Executive Officer and Executive Chairman. Mr. Bitterman has over 25 years of executive leadership experience in the pharmaceutical and biologic life science industry with a proven track record in operations, finance and investor relations. "While monoclonal antibody therapies are available for the treatment of cSCC, mechanistically they only block the interaction between PD-1 and PD-L1 on the cell surface. PH-762 also has the potential to address PD-1 inside the T cell, essentially further enhancing the activity of the T cell to kill the tumor cells," said Dr. James Cardia, Phio's Vice President of Scientific Operations. Dr. Cardia led the team that discovered INTASYL.
" PH-762 has the potential to meet a significant medical need in patients who have failed to respond to mAbs, as well as those with resectable and metastatic solid tumors. Phio is committed to advancing the study of PH-762 to provide a meaningful therapy for patients with a broad range of solid tumors."
December 21, 2022
December 20, 2022
December 19, 2022
December 16, 2022
December 15, 2022
December 14, 2022
December 13, 2022
December 12, 2022
Events
See All
Trail Blazers
See All
Guest Authors
See All